Literature DB >> 2871254

Very-low-dose cytarabine for myelodysplastic syndromes and acute myeloid leukaemia in the elderly.

A Worsley, G J Mufti, J A Copplestone, D G Oscier, T J Hamblin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2871254     DOI: 10.1016/s0140-6736(86)91061-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Interleukin 4 suppresses the spontaneous growth of chronic myelomonocytic leukemia cells.

Authors:  K Akashi; T Shibuya; M Harada; Y Takamatsu; N Uike; T Eto; Y Niho
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

2.  Low dose cytosine arabinoside in the treatment of myeloid leukaemias and myelodysplastic syndromes.

Authors:  M Murray; P Sarsfield; E Lawlor; S R McCann
Journal:  Ir J Med Sci       Date:  1988-07       Impact factor: 1.568

Review 3.  Refractory anaemias.

Authors:  A K Saraya; P S Dhot; R Saxena
Journal:  Indian J Pediatr       Date:  1993 Mar-Apr       Impact factor: 1.967

4.  Maintenance with low-dose cytarabine for acute myeloid leukemia in complete remission.

Authors:  E Archimbaud; B Anglaret; X Thomas; J Jaubert; C Sebban; D Guyotat; D Fiere
Journal:  Ann Hematol       Date:  1992-08       Impact factor: 3.673

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.